A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical illness

Critical Care Medicine

Volumn 42, Issue 9, 2014, Pages 2048-2057

  Pieracci, Fredric M ^a   Stovall, Robert T ^a   Jaouen, Brant ^a   Rodil, Maria ^a   Cappa, Anthony ^a   Burlew, Clay Cothren ^a   Holena, Daniel N ^b   Maier, Ronald ^c   Berry, Stepheny ^d   Jurkovich, Jerry ^a   Moore, Ernest E ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

anemia; iron supplementation; iron deficient erythropoiesis; randomized clinical trial; red blood cell transfusion

Indexed keywords

ANTIBIOTIC AGENT; ERYTHROCYTE PROTOPORPHYRIN; FERRITIN; HEMOGLOBIN; IRON SACCHARATE; PLACEBO; PROTOPORPHYRIN ZINC; TRANSFERRIN;

ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DIET SUPPLEMENTATION; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FALLING; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HOSPITAL ADMISSION; HUMAN; HYPERFERRITINEMIA; HYPOTHESIS; INFECTION RISK; INJURY; INJURY SCALE; INJURY SEVERITY; INTENSIVE CARE UNIT; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PENETRATING TRAUMA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TRAFFIC ACCIDENT; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; APACHE; CRITICAL ILLNESS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEMALE; FERRIC COMPOUNDS; GLUCARIC ACID; HEMATINICS; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROTOPORPHYRINS; SINGLE-BLIND METHOD; TRANSFERRIN; TRAUMA CENTERS; YOUNG ADULT;

EID: 84906789925     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000408     Document Type: Article

References (49)

1. Vincent JL, Baron JF, Reinhart K, et al; ABC (Anemia and Blood Transfusion in Critical Care) Investigators: Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507
2. DeBellis RJ: Anemia in critical care patients: Incidence, etiology, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 2007; 64:S14-21; quiz S28
3. Napolitano LM: Epoetin alfa in the critically ill: What dose? Which route? Crit Care Med 2009; 37:1501-1503
4. Pieracci FM, Barie PS: Diagnosis and management of iron-related anemias in critical illness. Crit Care Med 2006; 34:1898-1905
5. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783-788
6. Pieracci FM, Eachempati SR, Henderson P, et al: Prevalence of hypoferremia and iron-deficient erythropoiesis in anemic critically ill patients, and correlation with severity of illness. Crit Care Med 2006; 34:A132
7. Hastka J, Lasserre JJ, Schwarzbeck A, et al: Central role of zinc protoporphyrin in staging iron deficiency. Clin Chem 1994; 40:768-773
8. Cappa AR, Jaouen BM, Moore EE, et al: Prevalence of hypoferremia and iron-deficienct erythropoiesis in anemic critically ill trauma patients early after admission, and correlation with severity of illness. J Surg Res 2012; 179:A199
9. Lasocki S, Garnier M, Ley L, et al: [How is iron prescribed in French ICUs: A practice survey]. Ann Fr Anesth Reanim 2008; 27:909-914
10. Lapointe M: Iron supplementation in the intensive care unit: When, how much, and by what route? Crit Care 2004; 8(Suppl 2):S37-S41
11. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al: Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28:2773-2778
12. Thomas J, Martinez A: Blood conservation in the critically ill. Am J Health Syst Pharm 2007; 64:S11-S18
13. Pieracci FM, Barie PS: Iron and the risk of infection. Surg Infect (Larchmt) 2005; 6(Suppl 1):S41-S46
14. Pieracci FM, Henderson P, Rodney JR, et al: Randomized, doubleblind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. Surg Infect (Larchmt) 2009; 10:9-19
15. Nemeth E, Rivera S, Gabayan V, et al: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271-1276
16. Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials): The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285:1987-1991
17. Lipsett PA, Swoboda SM, Dickerson J, et al: Survival and functional outcome after prolonged intensive care unit stay. Ann Surg 2000; 231:262-268
18. Nasraway SA Jr, Hudson-Jinks TM, Kelleher RM: Multidisciplinary care of the obese patient with chronic critical illness after surgery. Crit Care Clin 2002; 18:643-657
19. Takala J, Ruokonen E, Webster NR, et al: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785-792
20. Garner JS, Jarvis WR, Emori TG, et al: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-140
21. Fishbane S, Kowalski EA: The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000; 13:381-384
22. Silverstein SB, Rodgers GM: Parenteral iron therapy options. Am J Hematol 2004; 76:74-78
23. Van Wyck DB, Cavallo G, Spinowitz BS, et al: Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000; 36:88-97
24. Georgopoulos D, Matamis D, Routsi C, et al; Critical Care Clinical Trials Greek Group: Recombinant human erythropoietin therapy in critically ill patients: A dose-response study [ISRCTN48523317]. Crit Care 2005; 9:R508-R515
25. Bleackley MR, Wong AY, Hudson DM, et al: Blood iron homeostasis: Newly discovered proteins and iron imbalance. Transfus Med Rev 2009; 23:103-123
26. Charlson M, Szatrowski TP, Peterson J, et al: Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245-1251
27. Gaweda AE, Bhat P, Maglinte GA, et al: TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients. Hemodial Int 2014;18:38-46
28. Metzgeroth G, Adelberger V, Dorn-Beineke A, et al: Soluble transferrin receptor and zinc protoporphyrin-competitors or efficient partners? Eur J Haematol 2005; 75:309-317
29. Hébert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409-417
30. Croce MA, Fabian TC, Mueller EW, et al: The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures. J Trauma 2004; 56:931-934; discussion 934-936
31. Kleinbaum DG, Kupper LL, Muller KE: Applied Regression Analysis and Other Multivariable Methods. Second Edition. The Duxbury series in statistics and decision sciences. Boston, MA, PWS-Kent Pub, 1988, pp 718, xviii
32. Bateman AP, McArdle F, Walsh TS: Time course of anemia during six months follow up following intensive care discharge and factors associated with impaired recovery of erythropoiesis. Crit Care Med 2009; 37:1906-1912
33. Napolitano LM, Kurek S, Luchette FA, et al; American College of Critical Care Medicine of the Society of Critical Care Medicine; Eastern Association for the Surgery of Trauma Practice Management Workgroup: Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009; 37: 3124-3157
34. Hill GE, Frawley WH, Griffith KE, et al: Allogeneic blood transfusion increases the risk of postoperative bacterial infection: A meta-analysis. J Trauma 2003; 54:908-914
35. Malone DL, Dunne J, Tracy JK, et al: Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 2003; 54:898-905; discussion 905-907
36. Bochicchio GV, Napolitano L, Joshi M, et al: Outcome analysis of blood product transfusion in trauma patients: A prospective, riskadjusted study. World J Surg 2008; 32:2185-2189
37. Bochicchio GV, Napolitano L, Joshi M, et al: Blood product transfusion and ventilator-associated pneumonia in trauma patients. Surg Infect (Larchmt) 2008; 9:415-422
38. Offner PJ, Moore EE, Biffl WL, et al: Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg 2002; 137:711-716; discussion 716-717
39. Silliman CC, Moore EE, Johnson JL, et al: Transfusion of the injured patient: Proceed with caution. Shock 2004; 21:291-299
40. Nicolas G, Chauvet C, Viatte L, et al: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110:1037-1044
41. Weinstein DA, Roy CN, Fleming MD, et al: Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. Blood 2002; 100:3776-3781
42. Nemeth E, Valore EV, Territo M, et al: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101:2461-2463
43. Silverberg DS, Iaina A, Schwartz D, et al: Intravenous iron in heart failure: Beyond targeting anemia. Curr Heart Fail Rep 2011; 8:14-21
44. Piagnerelli M, Vincent JL: Role of iron in anaemic critically ill patients: It's time to investigate! Crit Care 2004; 8:306-307
45. Corwin HL, Gettinger A, Fabian TC, et al; EPO Critical Care Trials Group: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357:965-976
46. Corwin HL, Gettinger A, Pearl RG, et al; EPO Critical Care Trials Group: Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002; 288: 2827-2835
47. Corwin HL, Gettinger A, Rodriguez RM, et al: Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, doubleblind, placebo-controlled trial. Crit Care Med 1999; 27:2346-2350
48. Minutolo R, Locatelli F, Gallieni M, et al: Anaemia management in non-dialysis chronic kidney disease (CKD) patients: A multicentre prospective study in renal clinics. Nephrol Dial Transplant 2013; 28:3035-3045
49. Guo W, Bachman E, Li M, et al: Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell 2013; 12:280-291